These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37586436)

  • 1. Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models.
    Li C; Chen L; Li L; Chen W
    Eur J Pharm Sci; 2023 Oct; 189():106564. PubMed ID: 37586436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of modeling and simulation to predict the influence of triazole antifungal agents on the pharmacokinetics of zanubrutinib and acalabrutinib.
    Chen L; Li C; Bai H; Li L; Chen W
    Front Pharmacol; 2022; 13():960186. PubMed ID: 36299883
    [No Abstract]   [Full Text] [Related]  

  • 3. Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.
    Wang Z; Chan ECY
    Clin Pharmacol Ther; 2022 Oct; 112(4):803-807. PubMed ID: 35712802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics.
    Sagawa K; Lin J; Jaini R; Di L
    Pharm Res; 2023 Aug; 40(8):1927-1938. PubMed ID: 37231296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
    Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
    J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.
    Pilla Reddy V; Fretland AJ; Zhou D; Sharma S; Chen B; Vishwanathan K; McGinnity DF; Xu Y; Ware JA
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):451-464. PubMed ID: 34080039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
    Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
    Kilford P; Khoshaein N; Southall R; Gardner I
    Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):699-710. PubMed ID: 35840839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modeling to assess the drug-drug interactions of anaprazole with clarithromycin and amoxicillin in patients undergoing eradication therapy of H. pylori infection.
    Liang N; Zhou S; Li T; Zhang Z; Zhao T; Li R; Li M; Shao F; Wang G; Sun J
    Eur J Pharm Sci; 2023 Oct; 189():106534. PubMed ID: 37480962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.
    Anwar K; Nguyen L; Nagasaka M; Ou SI; Chan A
    JTO Clin Res Rep; 2023 Feb; 4(2):100452. PubMed ID: 36568522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
    Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
    Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the interaction between nifedipine- and ritonavir-containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis.
    Niu W; Li S; Jin S; Lin X; Zhang M; Cai W; Jiao Z; Xiang X
    Br J Clin Pharmacol; 2021 Jul; 87(7):2790-2806. PubMed ID: 33269470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
    Colbers A; Greupink R; Litjens C; Burger D; Russel FG
    Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
    Conner TM; Reed RC; Zhang T
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
    Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
    Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.